Uterotonics in Obstetric Practice: From Past to Present

This material covers the history, pharmacology, and evidence-based use of uterotonic drugs for preventing and managing postpartum hemorrhage (PPH). It emphasizes the shift from traditional bolus injections to safer, controlled infusions, particularly for oxytocin, and introduces alternative agents.

Understanding Postpartum Hemorrhage (PPH) and Uterine Physiology

What is Postpartum Hemorrhage (PPH) and how is it defined?

Postpartum hemorrhage is defined as bleeding from the genital tract following delivery. For a vaginal delivery, blood loss of 500 ml or more is considered PPH. For a Cesarean delivery, the threshold is 1,000 ml. In the Indian context, for anemic women, a loss of even 300 ml is considered significant PPH.

What are the two types of PPH based on timing?

Primary PPH occurs within the first 24 hours after delivery and is the main concern for anesthesiologists. Secondary PPH occurs after 24 hours and up to 4-6 weeks postpartum.

What are the "Four T's" that cause PPH, and which one is most common?

The causes of PPH are taught as the "Four T's":

Tone: Loss of uterine tone (atony), which is the most common cause, responsible for 80% of PPH cases.
Trauma: Injuries to the genital tract.
Tissue: Retained placental tissue.
Thrombin: Coagulation disorders.

This lecture focuses on "Tone."

What is the normal physiological mechanism that prevents PPH after delivery?

After the baby is delivered, the body naturally releases oxytocin and prostaglandins. Oxytocin causes rhythmic contractions and relaxations, while prostaglandins cause sustained (tetanic) contractions. These hormones work together to contract the uterus. The uterus has three muscle layers: longitudinal outer fibers, a crucial middle layer with crisscrossing fibers that constrict blood vessels, and circular inner fibers. This complete contraction acts as a "living ligature" to stop bleeding.

What is active management of the third stage of labor?

Active management is a preventive approach where obstetricians take proactive measures to prevent PPH rather than waiting for it to occur. The three cornerstones (or pillars) are:

Massage of the uterus.
Controlled cord traction to deliver the placenta (done carefully to avoid worsening hemorrhage).
Prophylactic use of uterotonics.

Oxytocin: Pharmacology, Proper Use, and Common Misconceptions

What is an oxytocic drug and what are the three main classes?

An oxytocic is any drug that promotes contraction of the uterus. The three main classes of uterotonic drugs are:

Oxytocin and its analogues (e.g., Oxytocin, Carbetocin).
Ergot alkaloids (e.g., Methylergonovine / Methergine).
Prostaglandins (e.g., Carboprost, Misoprostol).

What are the key pharmacological properties of oxytocin that influence its use?

Oxytocin is a naturally occurring hormone with a very short half-life of about 6 minutes. Because of this, it is more effective when given as an infusion rather than a bolus. The synthetic form is known as Pitocin or Syntocinon. It requires a strict cold chain (2-6°C) for transport and storage to maintain its potency; exposure to room temperature degrades the drug.

What is the traditional, incorrect way of administering oxytocin?

The traditional and incorrect method, once common practice, was to give a 5 or 10-unit IV bolus injection followed by adding the rest of the ampule to IV fluids and running it rapidly. This practice is now considered wrong due to the drug's short half-life and significant side effects.

What are the dangers of giving oxytocin as a rapid IV bolus?

Administering oxytocin as a bolus can cause severe unwanted effects including vasodilation, tachycardia, hypotension, and in critical situations, it may even lead to cardiac arrest.

What is the evidence-based "Rule of Threes" for oxytocin administration?

The "Rule of Threes," proposed by Sen and Balki, provides a simple and safe regimen:

Dilute 30 international units of oxytocin in 500 ml of isotonic saline (not dextrose). This creates a concentration of 3 units in 50 ml.
Administer 50 ml (3 units) over 15-20 seconds.
Repeat this dose again after 3 minutes, and then again after another 3 minutes (total of 3 doses / 9 units).
If the uterus remains flabby after three doses, consider alternative uterotonics.
Once adequate contraction is achieved, continue the infusion at a rate of 3 international units per hour for the next 5 hours.

What are the recommended oxytocin infusion rates for different patient categories?

For a Cesarean delivery:

Patients with no prior oxytocin exposure: Start the infusion at 0.3 IU/min. If atony persists, double the dose to 0.6 IU/min, and again to 0.9 IU/min if needed.
Patients with prior oxytocin exposure (during labor): Start at a higher rate of 0.6 IU/min, as receptor sensitivity is reduced. Increase to 0.9 IU/min if needed.

If the uterus does not contract after these measures, alternative drugs should be considered.

Alternative and Backup Uterotonic Agents

What is Carbetocin and what are its advantages over oxytocin?

Carbetocin is a long-acting synthetic analogue of oxytocin. Its key advantage is that it is heat-stable, remaining effective for 36 months at up to 30°C, unlike oxytocin which requires refrigeration. It is typically given as a 100 microgram dose. It serves as a good alternative, especially in settings where maintaining a cold chain is difficult.

What is Methylergonovine (Methergine) and how should it be used?

Methylergonovine is an ergot alkaloid and a common first-line backup uterotonic. It produces a sustained, tetanic uterine contraction. It is given as a 0.2 mg intramuscular (IM) injection.

Critical Warning: It must never be given intravenously (IV).
Contraindication: It should be avoided in hypertensive patients, including those with pre-eclampsia or eclampsia.

What is Carboprost and when is it indicated?

Carboprost is a synthetic analogue of prostaglandin F2 alpha. It is a potent uterotonic, available as 0.25 mg ampules. Doses can be repeated every 15-30 minutes, up to a total of 8 doses (2 mg). It is given IM (or intramyometrially by the surgeon) and must never be given IV. It is contraindicated in patients with asthma as it can cause bronchospasm.

What is Misoprostol and why is it useful in resource-poor settings?

Misoprostol is a prostaglandin E1 analogue. Its main advantages are:

Heat stability: It does not require a cold chain.
Multiple routes of administration: It can be given rectally, sublingually, or buccally, making it usable by midwives and in peripheral health centers.
It serves as a valuable "last resort" option, especially in tropical countries, to stabilize a patient with PPH before transfer to a higher-level facility.

Key Takeaways and Practice Change

What is the single most important practice change recommended in this lecture?

The most critical change is to move away from giving oxytocin as a rapid IV bolus and instead adopt an evidence-based approach of administering it as a controlled, slow infusion (e.g., the "Rule of Threes") to ensure efficacy and patient safety. Education and collaboration between anesthesiologists and obstetricians are key to implementing this change.